An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination

Abstract: Competition among pharmaceutical companies to develop safe and effective vaccines against SARS-CoV-2 is high. However, based on the prior experience with the influenza vaccine, up to 50% in lack of effectiveness would be found among healthy adults receiving effective vaccines against SARS-CoV-2. There is growing evidence that insufficient sleep may potentially be a pervasive and prominent factor accounting for this variability. Individuals experiencing total or partial sleep loss exhibit markedly reduced antigen-specific antibodies as compared to healthy sleepers. Besides, pre-vaccination sleep quality is also an important contributing factor. Several meta-analyses and expert consensus reports support the view that the chronobiotic/hypnotic properties of melatonin are useful in patients with primary sleep disorders to decrease sleep onset latency and to increase total sleep time. Hence, the prescription of melatonin for at least 2 weeks prior to vaccination can be a useful approach to improve sleep quality and to ensure that the vaccination is performed at a moment of optimal sleep conditions. Moreover, melatonin enhances the immune response to vaccines by increasing peripheral blood CD4+ T cells and IgG-expressing B cells. Administration of exogenous melatonin could increase the potency of the immune response and the duration of the immunity induced by the vaccine. Besides, melatonin could also prevent adverse effects of the vaccination due to its antioxidant and immunomodulatory properties. Therefore, the administration of melatonin from 2 weeks to at least 4 weeks after vaccination may constitute an effective means to enhance the efficacy of vaccination against SARS-CoV-2.

Guardado en:
Detalles Bibliográficos
Autores principales: Cardinali, Daniel Pedro, Brown, Gregory M., Pandi Perumal, Seithikurippu R.
Formato: Artículo biblioteca
Idioma:eng
Publicado: ST-Bio-Life LLC 2021
Materias:COVID-19, SARS-CoV-2, MELATONINA, INSOMNIO, SUEÑO, VACUNACION,
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/13669
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:ucacris:123456789-13669
record_format koha
spelling oai:ucacris:123456789-136692022-03-31T18:56:20Z An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination Cardinali, Daniel Pedro Brown, Gregory M. Pandi Perumal, Seithikurippu R. COVID-19 SARS-CoV-2 MELATONINA INSOMNIO SUEÑO VACUNACION Abstract: Competition among pharmaceutical companies to develop safe and effective vaccines against SARS-CoV-2 is high. However, based on the prior experience with the influenza vaccine, up to 50% in lack of effectiveness would be found among healthy adults receiving effective vaccines against SARS-CoV-2. There is growing evidence that insufficient sleep may potentially be a pervasive and prominent factor accounting for this variability. Individuals experiencing total or partial sleep loss exhibit markedly reduced antigen-specific antibodies as compared to healthy sleepers. Besides, pre-vaccination sleep quality is also an important contributing factor. Several meta-analyses and expert consensus reports support the view that the chronobiotic/hypnotic properties of melatonin are useful in patients with primary sleep disorders to decrease sleep onset latency and to increase total sleep time. Hence, the prescription of melatonin for at least 2 weeks prior to vaccination can be a useful approach to improve sleep quality and to ensure that the vaccination is performed at a moment of optimal sleep conditions. Moreover, melatonin enhances the immune response to vaccines by increasing peripheral blood CD4+ T cells and IgG-expressing B cells. Administration of exogenous melatonin could increase the potency of the immune response and the duration of the immunity induced by the vaccine. Besides, melatonin could also prevent adverse effects of the vaccination due to its antioxidant and immunomodulatory properties. Therefore, the administration of melatonin from 2 weeks to at least 4 weeks after vaccination may constitute an effective means to enhance the efficacy of vaccination against SARS-CoV-2. 2022-03-22T12:59:34Z 2022-03-22T12:59:34Z 2021 Artículo Cardinali, D. P., Brown, G. M., Pandi Perumal, S. R. An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination [en línea]. Melatonin Research. 2021, 4 (1). doi: 10.32794/mr11250091. doi: 10.32794/mr11250091. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13669 2641-0281 (online) https://repositorio.uca.edu.ar/handle/123456789/13669 10.32794/mr11250091 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf ST-Bio-Life LLC Melatonin Research Vol. 4, No.1, 2021
institution UCA
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-uca
tag biblioteca
region America del Sur
libraryname Sistema de bibliotecas de la UCA
language eng
topic COVID-19
SARS-CoV-2
MELATONINA
INSOMNIO
SUEÑO
VACUNACION
COVID-19
SARS-CoV-2
MELATONINA
INSOMNIO
SUEÑO
VACUNACION
spellingShingle COVID-19
SARS-CoV-2
MELATONINA
INSOMNIO
SUEÑO
VACUNACION
COVID-19
SARS-CoV-2
MELATONINA
INSOMNIO
SUEÑO
VACUNACION
Cardinali, Daniel Pedro
Brown, Gregory M.
Pandi Perumal, Seithikurippu R.
An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
description Abstract: Competition among pharmaceutical companies to develop safe and effective vaccines against SARS-CoV-2 is high. However, based on the prior experience with the influenza vaccine, up to 50% in lack of effectiveness would be found among healthy adults receiving effective vaccines against SARS-CoV-2. There is growing evidence that insufficient sleep may potentially be a pervasive and prominent factor accounting for this variability. Individuals experiencing total or partial sleep loss exhibit markedly reduced antigen-specific antibodies as compared to healthy sleepers. Besides, pre-vaccination sleep quality is also an important contributing factor. Several meta-analyses and expert consensus reports support the view that the chronobiotic/hypnotic properties of melatonin are useful in patients with primary sleep disorders to decrease sleep onset latency and to increase total sleep time. Hence, the prescription of melatonin for at least 2 weeks prior to vaccination can be a useful approach to improve sleep quality and to ensure that the vaccination is performed at a moment of optimal sleep conditions. Moreover, melatonin enhances the immune response to vaccines by increasing peripheral blood CD4+ T cells and IgG-expressing B cells. Administration of exogenous melatonin could increase the potency of the immune response and the duration of the immunity induced by the vaccine. Besides, melatonin could also prevent adverse effects of the vaccination due to its antioxidant and immunomodulatory properties. Therefore, the administration of melatonin from 2 weeks to at least 4 weeks after vaccination may constitute an effective means to enhance the efficacy of vaccination against SARS-CoV-2.
format Artículo
topic_facet COVID-19
SARS-CoV-2
MELATONINA
INSOMNIO
SUEÑO
VACUNACION
author Cardinali, Daniel Pedro
Brown, Gregory M.
Pandi Perumal, Seithikurippu R.
author_facet Cardinali, Daniel Pedro
Brown, Gregory M.
Pandi Perumal, Seithikurippu R.
author_sort Cardinali, Daniel Pedro
title An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
title_short An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
title_full An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
title_fullStr An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
title_full_unstemmed An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
title_sort urgent proposal for the immediate use of melatonin as an adjuvant to anti- sars-cov-2 vaccination
publisher ST-Bio-Life LLC
publishDate 2021
url https://repositorio.uca.edu.ar/handle/123456789/13669
work_keys_str_mv AT cardinalidanielpedro anurgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination
AT browngregorym anurgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination
AT pandiperumalseithikurippur anurgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination
AT cardinalidanielpedro urgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination
AT browngregorym urgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination
AT pandiperumalseithikurippur urgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination
_version_ 1756276477394944000